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Background: Pre-mRNAs of 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)-propanoic acid (AMPA)/kainate glutamate
receptors undergo post-transcriptional modification known as RNA editing that is mediated by adenosine deaminase
acting on RNA type 2 (ADAR2). This modification alters the amino acid sequence and function of the receptor.
Glutamatergic signaling has been suggested to have a role in mood disorders and schizophrenia, but it is unknown
whether altered RNA editing of AMPA/kainate receptors has pathophysiological significance in these mental disorders.
In this study, we found that ADAR2 expression tended to be decreased in the postmortem brains of patients with
schizophrenia and bipolar disorder.
Results: Decreased ADAR2 expression was significantly correlated with decreased editing of the R/G sites of AMPA
receptors. In heterozygous Adar2 knockout mice (Adar2+/− mice), editing of the R/G sites of AMPA receptors was
decreased. Adar2+/− mice showed a tendency of increased activity in the open-field test and a tendency of resistance
to immobility in the forced swimming test. They also showed enhanced amphetamine-induced hyperactivity. There
was no significant difference in amphetamine-induced hyperactivity between Adar2+/− and wild type mice after the
treatment with an AMPA/kainate receptor antagonist, 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline.
Conclusions: These findings collectively suggest that altered RNA editing efficiency of AMPA receptors due to
down-regulation of ADAR2 has a possible role in the pathophysiology of mental disorders.
Keywords: RNA editing, Adenosine deaminase acting on RNA type 2, AMPA/kainate receptors, Serotonin 2C receptorBackground
Mood disorders and schizophrenia are major psychiatric
diseases that cause severe psychosocial impairment. Be-
cause many antidepressant and antipsychotic drugs act
on the serotonin transporter and serotonin receptors,
the serotonin has been implicated as having a role in
these diseases [1]. However, among the drugs acting on
glutamate receptors, phencyclidine causes schizophrenia-
like psychosis [2] and ketamine has rapid antidepressive
efficacy [3]. These findings suggest a possible role of al-
tered glutamatergic neurotransmission in mood disorders
and schizophrenia [1].
To date, numerous studies using genome analysis,
positron emission tomography, and postmortem brain
analysis have revealed possible roles of serotonergic* Correspondence: kato@brain.riken.jp
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article, unless otherwise stated.and glutamatergic pathways in schizophrenia and mood
disorders [1]. However, the detailed molecular mechanisms
of these diseases have yet to be totally elucidated. Among
the receptors in these pathways, pre-mRNAs of the
serotonin 2C receptor (HTR2C) and two classes of iono-
tropic glutamate receptors, 2-amino-3-(3-hydroxy-5-
methyl-isoxazol-4-yl)-propanoic acid (AMPA) and kainate
receptors, undergo RNA editing [4,5].
RNA editing is a post-transcriptional modification of
pre-mRNA, which is mediated by adenosine deaminases
acting on RNA (ADAR) enzymes. Research has especially
focused on adenosine-to-inosine (A-to-I) editing of HTR2C
and AMPA/kainate receptors by ADAR2 [6]. HTR2C
undergoes editing at five sites (from A to E), which results
in amino acid changes and causes functional alteration.
Among the editing sites of AMPA/kainate receptors, two
sites (Q/R and R/G) that result in amino acid changes
and have functional significance, have been relatively
well studied. The Q/R site is almost 100% edited in
GRIA2, and loss of editing at this site causes enhancedd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Subjects for RNA editing and expression analysis
of ADARs
Bipolar disorder Schizophrenia Control Depression
Array Collection (all samples)
n 32 35 34 NA
Sex (F:M) 17:15 9:26 9:25
Agea) 45.6 ± 11.0 42.6 ± 8.5 44.1 ± 7.7
PMIb) 36.3 ± 17.9 31.4 ± 15.5 29.6 ± 13.0
Brain pHc) 6.43 ± 0.30g) 6.47 ± 0.24h) 6.60 ± 0.27
Array Collection (pH-adjusted)
n 19 24 29 NA
Sex (F:M) 11:8 9:15 6:23
Aged) 46.1 ± 9.9 42.6 ± 8.5 44.6 ± 7.7
PMIe) 39.9 ± 20.2 35.0 ± 14.8 30.2 ± 12.5
Brain pHf) 6.63 ± 0.15 6.61 ± 0.14 6.69 ± 0.17
Neuropathology Consortium Samplesi)
n 11 13 14 11
Sex (F:M) 3:8 5:8 5:9 5:6
Age 39.4 ± 12.4 43.5 ± 13.6 49.0 ± 10.4 46.3 ± 10.5
PMI 31.5 ± 15.5 33.0 ± 14.9 22.6 ± 9.2 27.0 ± 11.9
Brain pH 6.25 ± 0.20 6.15 ± 0.25 6.30 ± 0.21 6.18 ± 0.24
NA, not available.
a)One way ANOVA, F = 0.94, P = 0.39, b)F = 1.61, P = 0.20, c)F = 3.5, P = 0.031.
d)One-way ANOVA, F = 0.89, P = 0.41, e)One-way ANOVA, F = 2.2, P = 0.11.
f)One-way ANOVA, F = 1.7, P = 0.18, g)t = -2.4, P = 0.017 to control.
h)t = 2.0, P = 0.042 to control.
i)No significant difference among 4 groups were found for age, PMI, brain pH
by One-way ANOVA.
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The R/G site is not fully edited, which changes the kinetics
of desensitization [7].
Numerous studies have investigated altered RNA editing
of HTR2C in postmortem brains of patients with mental
disorders, but the findings have not been consistent. While
several studies did not show any specific alteration of
RNA editing in mental disorders [8-11], other studies
showed disease-specific alteration, such as increased D
site editing in depression and increased A site editing
in suicide completers [12], decreased B site editing in
schizophrenia [13], and increased E site and decreased
D site editing in depression [14]. Among these studies,
increased A site editing in suicide completers has been
shown to be relatively consistent [9,10,12,15]. A recent
study using a next-generation sequencer [11] showed no
robust alteration of RNA editing of HTR2C in schizophre-
nia and depression, except that a trend of decreased
editing at the C, D, and E sites in nonsuicidal depression
was found. However, a trend of increased A site editing in
depressive patients that died by suicide is compatible with
previous studies.
The number of studies regarding the RNA editing of
AMPA/kainate receptors is relatively small. While several
studies showed no alteration in schizophrenia [16,17] and
bipolar disorder [17], a recent study revealed altered
editing of the I/V site of GRIK2 in bipolar disorder [6].
The role of RNA editing of glutamate receptors has
drawn attention because the glutamatergic hypothesis
of mood disorders has recently been established [18].
As already mentioned, there is no consensus on what
kind of alteration of RNA editing is characteristic of
schizophrenia and mood disorders. Possible reasons for
such discordance include the effect of confounding factors
in postmortem brain studies, such as medication and
premortem or postmortem changes, and complex inter-
actions between the cause of death (such as suicide) and
mental disorders. Recently, Lyddon and colleagues argued
that there are two factors involved in the altered editing of
HTR2C in mood disorders; one is decreased ADAR2 ex-
pression associated with decreased RNA editing of HTR2C,
and the other is increased A site editing in suicide [15].
Collectively, it is difficult to elucidate how RNA editing
is related to mental disorders by postmortem brain
analysis alone. To understand the pathophysiological
significance of altered ADAR2 expression and RNA
editing in mental disorders, integration of human
postmortem brain analysis and animal model studies
is crucial. In this study, we investigated the possible
roles of altered ADAR2 expression and RNA editing of
AMPA/kainate glutamate receptors through an analysis
of these factors in human postmortem brains. Molecular,
behavioral, and pharmacological analyses of heterozy-
gous Adar2 knockout mice (Adar2+/− mice) were alsoconducted to elucidate the roles of RNA editing in
schizophrenia and mood disorders.
Results
Overview
We analyzed the gene expression levels of the ADAR2
and RNA editing status of AMPA/kainite glutamate re-
ceptors in two sets of postmortem human brain samples
donated by the Stanley Medical Research Institute, Array
Collection and Neuropathology Consortium (Table 1). To
elucidate the molecular neurobehavioral consequence of re-
duced ADAR2 expression, we analyzed the RNA editing sta-
tus of Htr2c and AMPA/kainate glutamate receptors in
Adar2+/− mice; the behavior of the mice was analyzed by a
comprehensive battery of behavioral tests. To further under-
stand the molecular basis of the hyperactivity of the mice,
pharmacological experiments using amphetamine and the
selective AMPA receptor antagonist, 2,3-dihydroxy-6-nitro-
7-sulfamoyl-benzo[f]quinoxaline (NBQX) were performed.
ADAR2 expression in human postmortem brains
In the Array Collection samples, there was a significant dif-
ference in the CFL1 (cofilin 1)-normalized ADAR2 expres-
sion level between diagnoses [one-way analysis of variance
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significantly lower ADAR2 expressions in both Glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH)- and CFL1-nor-
malized data (P < 0.05). Patients with bipolar disorder also
showed a nonsignificant trend in the same direction, and it
was close to significance (P= 0.05) for the CFL1-normalized
ADAR2 expression level (Table 2). There was a significant
correlation between brain pH and ADAR2 expression
(GAPDH-normalized ADAR2: r= 0.28, P= 0.001; CFL1-nor-
malized ADAR2: r= 0.222, P < 0.05). Because low pH in
brain affected the measurement of postmortem brain gene
expression [19], we selected samples with high brain pH
(pH 6.4 or higher). This threshold was determined in our
previous gene expression study [20]. We found that the re-
sults were similar after selection of high pH samples
(Table 2). A similar nonsignificant trend for decreased
ADAR2 expression was found in the Neuropathology Con-
sortium samples (Table 2). There was no significant differ-
ence of ADAR1 expression between diagnoses (Table 2).
RNA editing changes in Adar2+/− mice
The initial report showed that homozygous Adar2
knockout is lethal in mice due to seizures caused by aTable 2 Expression levels of ADARs in postmortem brains of p
Array collection samples
All samples (normalized by GAPDH)
Diagnosis ADAR1 ADAR2
Bipolar disorder 0.0219 ± 0.0090 0.0025 ± 0.
Schizophrenia 0.0216 ± 0.0086 0.0024 ± 0.
Control 0.0232 ± 0.0063 0.0029 ± 0.
One-way ANOVA NS F = 2.11, P
pH-adjusted (normalized by GAPDH)
Diagnosis ADAR1 ADAR2
Bipolar disorder 0.0028 ± 0.0010 0.0244 ± 0.
Schizophrenia 0.0025 ± 0.0008d) 0.0231 ± 0.
Control 0.0031 ± 0.0008 0.0238 ± 0.




Bipolar disorder 0.0025 ± 0.0016f) 0.0110 ± 0.
Depression 0.0030 ± 0.0012 0.0107 ± 0.
Schizophrenia 0.0029 ± 0.0006 0.0107 ± 0.
Control 0.0033 ± 0.0008 0.0119 ± 0.
One-way ANOVA NS NS
Values are given in ±mean SD.
a)t = 2.22, P = 0.029 to control, b)t = -1.92, P = 0.05 to control.
c)t = 2.90, P = 0.005 to control, d)t = -2.65, P = 0.01, e)t = -3.12, P = 0.003.
f)t = -1.70, P = 0.09 to control, g)t = -2.0, P = 0.06 to control.
NS: not significant.
For one of 13 subjects with schizophrenia in Neuropathology Consortium, data wasmarked decrease of the Q/R site of Gria2, which results
in enhanced Ca2+ permeability of the AMPA receptors
[21]. Adar2+/− mice showed less prominent alteration of
RNA editing and were viable. Thus, Adar2+/− might be a
better model for mental disorders.
We first characterized the effect of Adar2+/− on RNA
editing status. Examination of Htr2c editing revealed
that the E and C sites were not altered, whereas the A,
B, and D sites had significantly decreased editing effi-
ciency, except in the cerebellum, where only the D site
showed significant alteration (Figure 1a). The alteration
of the A and B sites was relatively modest (10% or less),
whereas the change in the D site was larger (up to 20%).
With regard to the AMPA/kainate receptors, the Q/R
site of Gria2 was almost fully edited (Figure 1b). Editing of
the Q/R sites of Grik1 and Grik2 was slightly decreased.
There are two alternative spliced isoforms of flip and flop
types that have different desensitization kinetics. Because
the R/G site is located just before this alternative spliced
exon [7], the R/G sites were separately examined for two
alternative spliced isoforms. We found that RNA editing
of the R/G site was generally decreased in both the flip
and flop isoforms for all receptors investigated (Gria2,atients with mental disorders
All samples (normalized by CFL1)
ADAR1 ADAR2
0011 0.0397 ± 0.0163 0.0046 ± 0.0018b)
0008a) 0.0393 ± 0.0192 0.0043 ± 0.0015c)
0009 0.0477 ± 0.0380 0.0054 ± 0.0015
= 0.120 NS F = 3.86, P = 0.024
pH-adjusted (normalized by CFL1)
ADAR1 ADAR2
0096 0.0050 ± 0.0016 0.0442 ± 0.0180
0088 0.0043 ± 0.0013e) 0.0401 ± 0.0149
0054 0.0054 ± 0.0014 0.0420 ± 0.0080
F = 4.37, P = 0.016 NS
Normalized by CFL1
ADAR1 ADAR2
0071 0.0122 ± 0.0097 0.0026 ± 0.0017g)
0036 0.0043 ± 0.0013e) 0.0039 ± 0.0012
0045 0.0151 ± 0.0051 0.0039 ± 0.0010
0054 0.0133 ± 0.0062 0.0037 ± 0.0010




















































































































































Figure 1 RNA editing of Htr2c and AMPA/kainate glutamate receptors in Adar2+/− mice. a) Htr2c. b) AMPA/kainate glutamate receptors.
P < 0.05 by Student t-test. Hip denotes hippocampus, Frontal denotes frontal cortex, and Cereb denotes cerebellum. White bars indicate the WT
mice, black bars indicate the Adar2+/− mice. Data represent mean and error bars indicated by standard errors (n = 10 for each genotype).
Kubota-Sakashita et al. Molecular Brain 2014, 7:5 Page 4 of 14
http://www.molecularbrain.com/content/7/1/5Gria3, and Gria4). The R/G site showed a 10–36% de-
crease except for Gria4 in the cerebellum, where minimal
or no alteration in editing efficiency was observed.
RNA editing in human postmortem brains
We previously reported RNA editing efficiency of
HTR2C in the Consortium samples, which showed an
increase at the D site in depression and an increase at
the A site in suicide completers [12]. In this study, we
measured the editing efficiency of AMPA/kainate recep-
tors in the same sample set. As expected, the Q/R sites
were almost fully edited in all groups. There was no sig-
nificant alteration in RNA editing of R/G sites, but there
was a tendency toward decreased editing efficiency in
mood disorders (Table 3). The editing efficiency at the
R/G site was significantly correlated with the ADAR2expression level for all transcripts investigated (r = 0.30–
0.64, P < 0.05 for GAPDH-normalized and r = 0.25–0.64,
P < 0.05 for CFL1-normalized data) (Table 3); however,
the Q/R site of GRIA2 was not (P > 0.05). As shown in
Figure 2, some of the patients showed a prominent de-
crease in both editing efficiency of R/G sites and ADAR2
expression levels.
Behavioral analysis of Adar2+/− mice
The present findings suggest that ADAR2 is down-
regulated in schizophrenia and bipolar disorder, which
correlates with decreased R/G site editing of AMPA re-
ceptors. Thus, decreased ADAR2 levels and the resultant
alteration of editing efficiency at the R/G sites of AMPA
receptors might have some pathophysiological signifi-
cance in mood disorders and schizophrenia. To test this,
Table 3 RNA editing of AMPA receptors in the postmortem brains of patients with mental disorders
R/G sites Q/R sites
GRIA2 flip GRIA2 flop GRIA3 flip GRIA3 flop GRIA4 flip GRIA4 flop GRIA2
Bipolar disorder 64.4 ± 16.4 54.4 ± 12.5 66.3 ± 9.5 79.4 ± 10.6 56.0 ± 17.1 64.8 ± 15.8 96.6 ± 3.4
Depression 62.5 ± 13.8 54.9 ± 5.3 61.9 ± 9.6 82.6 ± 7.7 55.0 ± 15.8 69.9 ± 10.7 97.6 ± 3.0
Schizophrenia 66.0 ± 10.8 53.7 ± 8.0 66.0 ± 5.9 83.5 ± 9.4 60.5 ± 9.7 71.5 ± 6.1 99.0 ± 1.9
Control 70.1 ± 4.8 58.1 ± 4.4 65.0 ± 12.1 85.5 ± 3.5 63.2 ± 9.5 71.2 ± 7.5 98.8 ± 2.3
r* (GAPDH) 0.508 0.476 0.300 0.644 0.527 0.565 ns
r* (CFL1) 0.477 0.430 0.251 0.642 0.509 0.600 ns
*r = Correlation coefficient between editing efficiency of AMPA receptors and ADAR2 expression level.
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Adar2+/− mice. The results are summarized in Figure 3.
In open-field test, RMANOVA with the intrasubject fac-
tor of time (1–20 min, df = 19) and the intersubject fac-
tor of genotype showed a trend-level effect of genotype
(F = 4.0, P = 0.054) for locomotor activity. The Adar2+/−
mice tended to be more hyperactive than the wild-type
(WT) mice (Figure 3a, t = 2.01, P = 0.05). No significant
difference was found in the rearing scores (Figure 3b).
There was no alteration in prepulse inhibition (Figure 3c),
which does not support the hypothesis that Adar2+/−
mice show schizophrenia-like sensorimotor gating ab-
normality. Among the factors affecting the results of
the open-field test, a possible effect of anxiety was not
supported because there was no significant alteration
by the elevated plus maze (Figure 3d, 3e). The Morris
water maze test did not show any difference, indicating
that there was no marked impairment in spatial mem-
ory (Figure 3f, 3g). No significant alteration in passive
avoidance test (Figure 3h) is in accordance with lack of
significant alteration in elevated plus maze test. In theADAR2/GAPDH



















Figure 2 RNA editing of GRIA2 R/G site and ADAR2 expression level in
of ADAR2 and editing efficacy at R/G sites of GRIA2. a) GRIA2, flip isoform. b
efficiency at the R/G site of GRIA2. The horizontal axis shows the mRNA exp
represents the one person’s editing efficacy at the R/G site of GRIA2 versus
disorder (n = 11), closed squares represent schizophrenia (n = 13), closed d
controls (n = 14). Correlation coefficients were r = 0.53 (P < 0.001) for the f
information of each subject was shown in Neuropathology Consortium samactive avoidance test, there was no significant time ×
genotype interaction in the avoidance latency or num-
ber of avoidances by repeated measures (RM) ANOVA
(RMANOVA) (Figure 3i, 3j). In the forced swimming
test (Figure 3k, 3l), the ratio of the immobility time on
the second day to that of the first day, which is an indi-
cator for behavioral despair, tended to be smaller in the
Adar2+/− mice (t = 1.9, P = 0.06). This suggests that
Adar2+/− mice showed a tendency of resistance to be-
havioral despair.
Pharmacological experiments
To further elucidate the mechanism of increased loco-
motor activity in Adar2+/− mice, we examined the effect
of amphetamine administration in the mice. Amphet-
amine is known to evoke a delayed overflow of glutam-
ate in the brain in addition to having an impact on the
dopaminergic system. It causes acute hyperactivity and
behavioral sensitization [22,23]. Less editing in the
GluR2 receptors would result in high Ca2+ permeability



















GRIA2 R/G flop 
human postmortem brains. Relationship between expression level
) GRIA2, flop isoform. The vertical axis means the RNA editing
ression of ADAR2 shown by the ADAR2/GAPDH ratio. Each dot
their expression level of ADAR2. Closed circles represent bipolar
iamonds represent depression (n = 11), and open circles represent
lip isoform and r = 0.42 (P < 0.005) for the flop isoform. The
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Figure 3 (See legend on next page.)
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Figure 3 Behavioral battery in Adar2+/− mice. a,b) Open-field test. The vertical axis is the counts measured by the interruption of infrared
beams. a) Locomotor activity. b) Rearing. Closed circles indicate the Adar2+/− mice (+/−). Open circles indicate the WT mice (+/+). No significant
genotype × time interaction was found for locomotor activity. Locomotor count tended to be higher in the Adar2+/− mice than that in the WT
mice (t = 2.0, P = 0.05). RMANOVA with the intrasubject factor of time (1–20 min, df = 19) and the intersubject factor of genotype showed no
significant effect of genotype or genotype × time interaction in rearing count. c) PPI test. There was no significant difference between genotypes.
d,e) Elevated plus maze test. d) Number of entries to open arms. e) Time spent on open arms. There was no significant difference in the number
of entries and time spent on open arms between genotypes. f,g) Morris water maze test. f) Escape latency. No significant effect of genotype was
found for the escape latency by RMANOVA. g) Probe test. There was no significant difference between genotypes. h) Passive avoidance test.
There was no significant effect of genotypes by two-way ANOVA. i,j) Active avoidance test. There was no significant interaction between time
(df = 14) and genotype (df = 1) in the avoidance latency (i) or number of avoidances (j) by RMANOVA (P = 0.05). k,l) Forced swimming test.
k) Duration of immobility. l) The ratio of immobility time on the second day to the first day. Data represent mean and error bars indicated by
standard errors (n = 16 for each genotype).
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that the AMPA receptor antagonist NBQX by itself had
no effect on locomotor activity but prevented hyper-
activity after treatment with amphetamine [24,25]. In ac-
cordance with previous studies, the locomotor activity
gradually declined in two groups with treatment of sa-
line or NBQX in both the WT and the Adar2+/− mice in
our experiment. There was no significant difference of
activity level between saline injection and NBQX injec-
tion both in the WT mice and the Adar2+/− mice [see
Additional file 1: Figure S1]. Thus, we examined this be-
havioral trait in relation to amphetamine treatment of
Adar2+/− mice. The amphetamine treatment enhanced
the activity level in both the WT and the Adar2+/− mice
(Figure 4a, 4b). RMANOVA showed significant effects of
genotype (df = 1, F = 17.8, P <0.005) and drug (df = 1,
F = 70.9, P < 0.001), as well as a significant interaction
of genotype × drug (df = 1, F = 7.1, P < 0.05). The en-
hancement was significantly larger in the Adar2+/− mice
than in the WT mice (Figure 4c, t = 3.07, P = 0.015).
Amphetamine treatment after the NBQX treatment also
enhanced the locomotor activity in the Adar2+/− mice
(9.03 ± 7.16) and the WT mice (7.51 ± 5.19) (Figure 4d,
4e). RMANOVA showed significant effects of drug (df =
1, F = 58.1, P < 0.001) but no significant effect of geno-
type (df = 1, F = 0.37, P=0.54) and no significant inter-
action of genotype × drug (df = 1, F = 0.29, P = 0.59).
There was no significant difference in the enhancement
between genotypes (Figure 4f, t = 0.146, P = 0.56).
Discussion
In this study, we performed an integrated analysis of
ADAR2 and RNA editing of AMPA/kainate glutamate
receptors in human postmortem brains and model mice.
Recent expression studies using postmortem brains
showed no significant alteration of ADAR2 [6,26] and
significant down-regulation of ADAR2 in major depres-
sive disorder [15]. In our study, although the results
were not consistent between two independent sample
sets, we observed general down-regulation of ADAR2 in
the brains of patients with schizophrenia or mooddisorders. The discrepancy in the results across studies
may be partly due to the complexity of ADAR2 tran-
scripts [27]. In this study, we examined the gene expres-
sion level of ADAR2 transcripts containing exons 11 and
12. Another notable feature was that some patients, but
not all patients, showed drastic down-regulation of
ADAR2, which was accompanied by decreased RNA
editing at the R/G sites.
To model the down-regulation of ADAR2 in patients
with mental disorders, we analyzed Adar2+/− mice. Al-
tered RNA editing of Htr2c was characterized by a rela-
tively large decrease at the D site with smaller changes
at the A and B sites. A decrease of D site editing in de-
pression has been reported in some [11,14], but not all
[9,10,12,15] studies. The altered RNA editing of AMPA/
kainate receptors in Adar2+/− mice was characterized by
preserved Q/R site editing of Gria2 and decreased edit-
ing of R/G sites. This is consistent with a previous study
using semiquantitative analysis of sequence chromato-
grams [21]. Although it is a limitation of the study that
we did not measure the protein levels of Adar2, the al-
teration of RNA editing status might suggests that hap-
loinsufficiency of Adar2 would cause a decrease of
Adar2 protein level and subsequently reduced Adar2 ac-
tivity in Adar2+/− mice [21]. Because there was some re-
sidual Q/R site editing of Gria2 in homozygous Adar2
knockout mice, Adar1 might also play some role in the
editing of this site as well as RNA editing of the R/G site
of AMPA receptors and Htr2c. However, Adar1 was not
upregulated in homozygous Adar2 knockout mice, sug-
gesting that compensatory upregulation of Adar1 do not
play a major role in RNA editing changes in Adar2+/−
mice.
In the postmortem brains of patients with schizophre-
nia and mood disorders, statistically significant alteration
of RNA editing of AMPA/kainate receptors was not
found. The lack of prominent alteration of the Q/R site
in schizophrenia is consistent with the pioneering work
of Akbarian and colleagues [16]. However, there was a
significant correlation between ADAR2 expression and
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Figure 4 Effects of amphetamine with or without NBQX pre-treatment on locomotor activity in Adar2+/− mice. a,b) Effect of amphetamine
on locomotor activity in the WT mice (a) and the Adar2+/− mice (b). The horizontal axis indicates the time before and after administration of
amphetamine or saline. The vertical axis indicates the activity level. Each dot represents the averaged activity level during the 5-min period. Closed
circles indicate amphetamine-injected group and open circles indicate saline-injected group. Arrow indicates the time of drug administration. c) The
vertical axis indicates the fold change of the averaged activity level during 50 min after the administration of amphetamine to the averaged activity
during 50 min before the treatment. *P = 0.05 by Student t-test. d,e) Effect of NBQX on amphetamine-induced hyperactivity in the WT mice (d) and
the Adar2+/− mice (e). The horizontal axis indicates the time before and after the administration of amphetamine or saline. The vertical axis indicates
the activity level. Each dot represents the averaged activity level during the 5-min period. Closed circles indicate the amphetamine injected group and
open circles indicate the saline-injected group. Arrows indicate the time of drug administration. The open arrow indicates the administration of NBQX
and the closed arrow indicates the injection of amphetamine or saline. f) The vertical axis indicates the fold change of the averaged activity level during
50 min after the administration of amphetamine to the averaged activity during the middle 50 min after the NBQX treatment. No significant difference
was found between genotypes. Data represent mean and error bars indicated by standard errors.
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functional impact on RNA editing, similar to that ob-
served in Adar2+/− mice. Indeed, the editing of R/G sites
tended to be decreased in mood disorders as a whole
(Table 3), and some patients showed markedly decreased
editing efficiency (Figure 2). Thus, down-regulation of
ADAR2 and the resultant decreased editing of R/G sites
might have some pathophysiological significance, at least
in a subgroup of patients. The causes of downregulation
of ADAR2 in these disorders are unknown. A recent
study searched for proteins regulating ADAR2 and found
three RNA binding proteins, RPS14, SFRS9 and DDX15
[28]. We previously performed gene ontology analysis ofdifferentially expressed genes in the postmortem brains
of patients with bipolar disorder and found that genes
related to RNA binding and RNA splicing were signifi-
cantly enriched [29]. Indeed, SFRS9, a splicing factor,
was downregulated in the postmortem brain of patients
with schizophrenia and bipolar disorder (unpublished
finding). Thus, RNA machinery might be somehow dys-
regulated in bipolar disorder and schizophrenia.
Lyddon and colleagues examined the RNA editing in
AMPA/kainate receptors in the same samples (i.e., the
Neuropathology Consortium samples) [17]. Their find-
ing that the flop isoform of GRIA3 and GRIA4 showed
higher R/G site editing compared with the flip isoform
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diagnosis did not affect the RNA editing efficiency,
which is compatible with the present finding that there
is no significant difference between diagnoses.
In this study, Adar2+/− mice showed slight tendencies
of altered behavior by comprehensive behavioral battery.
The Adar2+/− mice showed hyperactivity in the open-
field test, but they did not show altered prepulse inhib-
ition, a candidate endophenotype in schizophrenia.
Amphetamine-induced hyperactivity was significantly
enhanced in the Adar2+/− mice. However, the difference
in this enhancement was no longer significant after the
pretreatment with NBQX, an inhibitor of the AMPA/kai-
nate receptor. This suggests that the enhanced response to
amphetamine seen in Adar2+/− mice might be mediated
by the enhanced glutamatergic signaling caused by altered
function of AMPA receptors due to the decreased RNA
editing of these receptors. However, a possibility that
NBQX enhanced amphetamine-induced hyperactivity in
WT mice but not in Adar2+/− mice cannot be totally ruled
out, because we did not set a control group to examine
the effect of amphetamine after saline injection. Moreover,
editing of Htr2c was also affected by haploinsufficiency of
Adar2, and its contribution to the enhanced response can-
not be ruled out.
In addition to the HTR2C and AMPA/kainate recep-
tors, recent studies using next-generation sequencers
showed numerous previously unidentified editing sites
[30-34], although some of the initial findings could
contain false-positive sites [35,36]. In spite of the con-
troversy surrounding the bioinformatics analysis of
RNA–DNA differences, many other A-to-I editing sites
such as Cyfip2, Kcna1, Blcap, Gabra3, Flna, Flnb, and
Cadps, have been experimentally validated as target
editing sites of Adar2 [37]. Thus, alteration of RNA
editing of transcripts other than those for glutamate re-
ceptors and HTR2C can also contribute to the pheno-
types observed in this study.
Horsch and colleagues performed behavioral analysis
of homozygous Adar2 knockout mice under the back-
ground of homozygous knock-in alleles of an edited ver-
sion of Gria2 to rescue severe phenotypes due to loss of
Q/R site editing of Gria2 [37]. These mice had dramatic-
ally decreased R/G site editing of Gria2 (15%) and Gria4
(10%) as well as profound alterations in RNA editing of
Htr2c [21], and showed increased passive rotation in a
rotarod test, impaired hearing ability, increased raring in
open field test and impaired prepulse inhibition. Some
of these findings might be attributable to decreased edit-
ing of Htr2c. Adar2+/− mice did not show impairment in
hearing ability and prepulse inhibition or altered re-
sponse to open field test, possibly because of milder im-
pairment in RNA editing of Htr2c and/or R/G site of
AMPA receptors. However, regarding the open-field test,they showed increased rearing during the first 5 min but
did not show any alteration in locomotor activity [37].
This difference may be due to different methodologies;
however, less extensive editing abnormality in heterozy-
gous knockout might cause a different phenotype.
Another group generated transgenic mice expressing
Adar2 [38] and found that these mice showed increased im-
mobility time and decreased activity in the open-field test.
Pairing this information with our findings that Adar2+/−
mice showed a tendency of increased activity in the open-
field test and a tendency of resistance to immobility in the
forced swimming test, we can postulate that the levels of
Adar2 and the resultant RNA editing changes might be re-
lated to the activity level or liability to the behavioral despair
exhibited in the forced swimming test. In the Adar2 trans-
genic mice, editing of the A, C, D, and E sites of Htr2c was
also increased [39]. Together with the decreased editing of
A, B, and D sites in Adar2+/− mice, it is possible that altered
A and D site editing of Htr2c might also contribute to the
behavioral phenotypes of Adar2+/− mice.
At this stage, we should be cautious about directly con-
necting the behavioral features of mice such as activity in
open-field tests, forced swimming tests, and enhanced am-
phetamine response to mental disorders such as schizo-
phrenia, depression, or mania. To extend this preliminary
finding, other animal models and effects of psychotropic
medications should also be examined. In spite of its limita-
tions, the present study suggests that an altered expression
level of Adar2 due to haploinsufficiency affects the behav-
ior of mice at least partly through the altered RNA editing
efficiency of AMPA/kainate receptors.
Conclusion
In conclusion, ADAR2 expression is decreased in the
postmortem brains of patients with schizophrenia and
bipolar disorder, and decreased ADAR2 expression is
correlated with decreased RNA editing of the R/G site in
AMPA glutamate receptors. Adar2+/− mice showed de-
creased RNA editing of the R/G site of AMPA receptors.
These mice showed slight behavioral changes such as
hyperlocomotion in the open-field test, attenuated im-
mobility response to the forced swimming test, and en-
hanced response to amphetamine. The difference of
amphetamine response was not seen after the treatment
with the AMPA/kainate receptor antagonist, NBQX.
These findings collectively suggest a possible role of al-
tered RNA editing efficiency of AMPA receptors due to




Two sets of postmortem brain samples donated by the
Stanley Medical Research Institute were used for this
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was the Array Collection, consisting of 104 RNA sam-
ples extracted from the prefrontal cortex (Brodmann
area 46) (34 bipolar disorder, 35 schizophrenia and 35
controls). The other set comprised frozen brain tissue
samples (Brodmann area 10) from the Neuropathology
Consortium. They were derived from patients with bipolar
disorder (n = 15), major depression (n = 15), and schizo-
phrenia (n = 15) and 15 controls. Diagnoses had been
made according to the Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition [41]. Because of the
RNA quality obtained, 101 and 49 samples from the Array
Collection and Neuropathology Consortium, respectively,
could be used for this study (Table 1). Subjects’ demo-
graphic information is shown in Table 1. This study was
approved by the Ethics Committee of RIKEN.
Animals
Adar2 knockout mice were developed by Higuchi and
colleagues as described [21]. In brief, a targeting vector
to replace exon 4 of Adar2 with a PGK–neo gene was
used for generation of a targeted embryonic stem cell
line. Chimeric mice were generated by injection of this
clone into C57BL/6-derived blastocysts, and homozy-
gous Adar2 knockout mice were bred thereafter. Geno-
typing of the mice was performed as described [21].
The mice were maintained in a 12-h light/12-h dark
cycle. All animal experiments were approved by the local
animal experiment committees of RIKEN and the Be-
havioral and Medical Sciences Research Consortium
(BMSRC) (Akashi, Japan). Animal experiments were car-
ried out in accordance with the National Institutes of
Health Guide for the Care and Use of Laboratory Ani-
mals. All efforts were made to minimize the number of
animals used and their suffering.
Real-time quantitative reverse transcription polymerase
chain reaction analysis in human brain samples
Three to five micrograms of total RNA was used for cDNA
synthesis by oligo (dT) and SuperScript II reverse tran-
scriptase (Invitrogen, Carlsbad, CA). Reverse transcription
polymerase chain reaction (RT-PCR) using SYBER/GREEN
I (Applied Biosystems, Foster City, CA) was performed with
an ABI PRISM 7900HT (Applied Biosystems). The com-
parative Ct method was used for quantification according
to the manufacture’s protocol (Applied Biosystems). Meas-
urement of delta Ct was done at least in triplicate. Amplifi-
cation of the single product was confirmed by monitoring
the dissociation curve and by gel electrophoresis. We used
two control genes (GAPDH and CFL1) for normalization.
The validity of the use of CFL1 as an internal control gene
in postmortem brain samples has been shown previously
[20]. Primer sequences used for the measurement of
ADAR2 are shown in Additional file 2: Table S1.RNA editing analysis
RNA editing levels of GRIA2, GRIA3, and GRIA4 were
determined in human samples. In the case of mice, those
of Gria2, Gria3, Gria4, Grik1, and Grik2 as well as Htr2c
were determined. The primers used for this assay are
listed in Additional file 2: Table S1. Because of the limited
amount of RNA samples, RNA editing analysis in human
brain was performed only on the Neuropathology Consor-
tium samples by the primer extension combined with
denaturing high-performance liquid chromatography (PE-
DHPLC) method, according to a previous report [42]. In
brief, after RT-PCR, extension of the primer was per-
formed before the editing site, and it was terminated by
incorporation of ddNTPs. The reaction mixture was sepa-
rated and quantified by denaturing HPLC using a WAVE
DNA fragment analysis system with the DNASep column
(Transgenomic, Hillington, United Kingdom). The gradi-
ent was prepared by mixing buffer A [0.1 M triethylam-
monium acetate buffer (TEAA), pH 7.0] and buffer B
[25% acetonitrile in 0.1 M TEAA]. Extension products
were typically eluted using a linear gradient from 18% B to
38% B. RNA editing efficiency was calculated by compar-
ing the area of the peak corresponding to the edited and
nonedited extension products.
For the mouse study, heterozygous Adar2 knockout
mice (Adar2+/− (n = 10) and the WT littermates (n = 10)
were used for the RNA editing analysis by pyrosequencing
[43]. Each group included five males and five females.
Three brain areas (cerebral cortex, hippocampus, and
cerebellum) were dissected from the brain of each
mouse. RNA was extracted with TRIzol reagent (Invitro-
gen, Carlsbad, CA). In brief, after RT-PCR with a biotinyl-
ated primer, streptavidin-sepharose beads (GE Healthcare
Life Sciences, Uppsala, Sweden) and the binding buffer
(10 mM Tris–HCl, 1 mM EDTA, 2 M NaCl, 0.1% Tween
20 at pH 7.6) were mixed with the RT-PCR product. The
reaction mixture was placed onto a MultiScreen-HV clear
plate (Millipore, Billerica, MA). After applying the vac-
uum, the beads were treated with a denaturation solution
(0.2 N NaOH). The beads were then suspended in an-
nealing buffer (20 mM Tris-acetate, 2 mM Mg-acetate at
pH 7.6) containing a sequencing primer. The template-
sequencing primer mixture was transferred onto a PSQ96
Plate (Qiagen, Venlo, Netherlands). Sequencing reactions
were performed with a PSQ96 SNP Reagent Kit (Qiagen)
using PSQ96MA (Qiagen) according to the manufacturer’s
instructions.
Behavioral analyses
Behavioral analyses were performed at BMSRC (Akashi,
Japan) with Adar2+/− (n = 16) and the WT littermates
(n = 16). All were males, aged 8–10 weeks at the initiation
of the behavioral analyses. The analyses were performed in
the following order: open-field test, prepulse inhibition
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passive avoidance learning test, active avoidance learning
test, and forced swimming test.
Open-field test
A transparent cubic box without a top (30 × 30 × 30 cm)
was used. A 40-W white lamp provided room lighting,
which was approximately 110 lux on the floor of the
chamber. A fan attached to the upper part of the wall at
one end of the chamber presented a masking noise of
45 dB. Two infrared beams were set on each wall 2 cm
above the floor at intervals of 10 cm. The total number
of successive interceptions of the two adjoining beams
on each bank was scored as locomotion behavior. For
the rearing analysis, 12 more infrared ray beams at-
tached 4.5 cm above the floor at 2.5-cm intervals were
used. The total number of vertical beam interceptions
was scored as the rearing behavior. Each mouse was
allowed to explore freely in the open-field area for
20 min.
Startle response and PPI test
Using a transparent acrylic box (7 × 7 × 10 cm), the star-
tle response was detected by an accelerometer (GH-
313A, Keyence, Osaka, Japan) as vibration of the box.
The acoustic startle pulses of a broadband burst (115 dB,
50 ms) and tone prepulse (85 dB, 30 ms) were presented
by using a speaker located in front of the box. Prepulse
using light (30 ms) was also applied by a light-emitting
diode (LED); however, this was not used as data because it
was found that the light prepulse did not attenuate the
startle response.
At the beginning of the session, 40 startle pulses were
presented to test for basal startle responsiveness and its
habituation. The average values of eight blocks, consisting
of five startle pulses each, were used for the statistical ana-
lysis. After that, three different types of trials were per-
formed; that is, startle pulse alone (n = 12), startle pulse
preceded by a tone prepulse (n = 12), and startle pulse pre-
ceded by a light prepulse (n = 12). Prepulses were pre-
sented 50, 100, or 200 ms before the startle pulse. In total,
six types of prepulse (each n = 4) were applied. The mean
interval averaged 25 s (15–45 s) throughout the session.
The startle response was recorded for 200 ms with a sam-
pling frequency of 1000 Hz. The PPI test was assessed by
the ratio of the mean response of the trials with one type
of prepulse (n = 4) divided by the mean response of the tri-
als without prepulse (n = 12).
Elevated plus maze test
The maze consisted of four arms (two open arms and
two closed arms), 5 cm wide and 30 cm long with a gray
acrylic floor, which met at a 10 × 10 cm center zone. The
two closed arms had transparent walls (15 cm in height)on both sides, and the open arms had low walls (3 mm in
height) on both sides. The apparatus was mounted 75 cm
above the floor of the room. The room lighting was ap-
proximately 20 lux on the maze. A video camera was
placed 80 cm above the maze. A fan generated a masking
noise of 45 dB. The animal was placed gently onto the cen-
ter of the maze and was allowed to explore the maze freely
for 10 min. The number of entries into each arm and the
time spent in the open arms were videotape recorded.
Morris water maze test
A round pool, with a diameter of 95 cm and depth of
21.5 cm, was placed in the center of a 140 × 130 cm
room. A platform with a diameter of 11 cm was set in
one of the quadrants, 5 mm beneath the surface of black
water maintained at 21 ± 1°C. On the first to fifth days,
five trials per day were performed for the learning phase.
Each mouse was released in one of the three quadrants
of the pool without the platform, and the time to reach
the platform was measured. If the mouse could not
reach the platform within 60 s, the experimenter placed
the mouse on the platform. On the sixth day, a probe
test was performed to examine whether the mouse re-
membered the platform’s location. The mouse was re-
leased in the quadrant on the opposite side of the
platform, and its behavior for 60 s was videotaped. The
time the mouse stayed in the target quadrant where the
platform had been placed and the immobility time were
measured.
Passive avoidance learning test
A mouse was placed in a box consisting of two rooms
separated by a shutter; that is, light and dark compart-
ments (each 10 × 10 cm). In the acquisition trial, the
mouse was kept in the light compartment. Five seconds
later, the door to the dark compartment was opened.
When the mouse moved into the dark compartment the
shutter was closed and 10 s later an electrical shock
(160 V, 3 s) was delivered through the grid floor.
Twenty-four hours later each mouse was placed again in
the light compartment and the latency to enter the dark
compartment was recorded up to a maximum of 180 s.
Active avoidance learning test
The same apparatus used for passive avoidance learning
was also used in the active avoidance learning test; how-
ever, there was no shutter between the light and dark
compartments. The box was set in a soundproof cham-
ber and illuminated by a 20-W white light set on the
chamber. The ceiling of the dark room was made of
black acryl board and the ceiling of the light room was
transparent acryl board.
The training was performed for 3 days. On each day,
one session consisting of 50 trials was performed. In
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(85 dB) was followed by an unconditioned stimulus (US)
of a 140-V electrical shock. The US was given 5 s after
initiation of the CS and continued until the mouse es-
caped to the other compartment. If the mouse did not
move to the other compartment, the US lasted 15 s to-
gether with the CS. If the mouse moved within 5 s after
the CS, the CS was stopped and no US was given. The
time from the CS to the escape and the number of es-
capes were used to measure the learning performance.
Forced swimming test
The animals were placed in a square pool 24 × 24 cm in
size. The water temperature was maintained at 21°C. On
the first day, the mice were left in the pool for 20 min
and the mobility recorded during the first 5 min by the
video camera was assessed. On the second day the ani-
mals were placed in the pool for 5 min and the immobil-
ity time over 5 min was recorded. The immobility was
defined by two criteria: 1) no movement of the legs and
the tail and 2) a completely stationary state in the pool
or movement only by inertia from previous movement.
The immobility was assessed from the video by three in-
dependent raters. The median value of the three raters
was used for the analysis.
Pharmacological experiments
Pharmacological experiments were performed at the RIKEN
Brain Science Institute. For this analysis, Adar2+/− mice
(n = 34) and the WT littermates (n = 30) were analyzed.
The laboratory was air-conditioned and the temperature
and humidity were maintained at approximately 22–23°C
and 50–55%, respectively. Food and water were freely
available except during experimentation. All of the experi-
ments were conducted in the light phase (from 9:00 a.m.
to 6:00 p.m.), and the starting times of the experiments
were kept constant.
For analysis of locomotor activity, an apparatus for the
open-field test equipped with a small soundproof room
(185 × 185 × 225 cm) was used. Each field was made of
white plastic (50 × 50 × 40 cm) and illuminated by LEDs
(70 lux at the center of the field). The behavior of the
mouse was monitored by a charge-coupled device camera
placed on the ceiling of the rack for the open fields. The
distance traveled (cm) was analyzed every 5 min. Data were
collected and analyzed using an Image J OF4 (O’Hara &
Company, Ltd., Tokyo, Japan), which is a modified software
based on the public domain U.S. National Institutes of
Health (NIH) image program (developed at the NIH and
at http://rsb.info.nih.gov./nih-image/).
Amphetamine was dissolved in an aqueous 0.9% NaCl
solution (1 mg/mL). The stock solution was further di-
luted with the 0.9% NaCl solution to achieve a dose of
1.5 mg/kg in 200 μL for injection. The locomotoractivity of mice was observed for 50 min before subcuta-
neous administration of the amphetamine solution. In
the first experiment, the fold change of the activity over
50 min after the administration of amphetamine or sa-
line compared to the activity before treatment was used
as the index.
NBQX (2,3-dioxo-6-nitro-1,2,3,4- tetrahydrobenzo[f]
quinoxaline-7-sulfonamide) was dissolved in a saline so-
lution (0.9% NaCl in water) (100 mg/mL). This stock so-
lution was further diluted with the saline solution to
achieve an dose of 10 mg/kg in 200 μL for intraperito-
neal injection after a 50-min adaptation period. Fifty mi-
nutes after NBQX dosing, amphetamine or saline was
administered subcutaneously. The fold change of the ac-
tivity from 50 min after amphetamine treatment com-
pared to the locomotor activity during the middle 50
min after the NBQX treatment was used as an index.
These two experiments used independent mice. The first
experiment consisted of 11 WT and 10 Adar2+/− mice
and the second experiment consisted of 19 WT and 24
Adar2+/− mice.
Statistical analyses
For the statistical analysis, two-sample t-test, Pearson’s coef-
ficient of correlation, one-way ANOVA, two-way ANOVA,
and RMANOVA were used. For statistical analysis of be-
havioral battery, at first RMANOVA with factors of time
and genotype was applied. When a statistically significant
interaction was detected, further post hoc analysis by
t-test was applied. The statistical analyses were performed
using IBM SPSS Statistics version 20 (IBM Corporation,
New York).
Additional files
Additional file 1: Figure S1. No significant effect of NBQX on
locomotor activity in both WT and Adar2+/− mice. Treatment with NBQX
does not suppress a locomotor activity in both WT and Adar2+/− mice.
Additional file 2: Table S1. List of primers used in this study. Forward
and reverse primer sets used in RNA editing analysis and RT-PCR for
human and mouse samples.
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